# RNN 1st Gen Model Johnson & Johnson Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
May 3, 2018
0.87%Expected margin
77.78% successful of 36 deals
$ 160.12 Last close price
at 18-oct-2021


Model's trade recommendations 1.07% Return for period

1.13% Annual return

$424.62B Market Cap

β 0.73  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 1.07%
52wk return -2.98%
52wk Range
Sortino ratio 0.18
Sharpe ratio 0.16
Norm. RMSE 0.41%
Downside risk 5.44%
Volatility 0.00%
  • 4.24 (2.63%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Johnson & Johnson (JNJ) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 10, 2014.

Market data for JNJ model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for JNJ.

Model is being retrained on a daily basis.

Float 2625M
P/E 17.67
Shares Outstanding 2632M
% Held by Insiders 0.30%
% Held by Institutions 67.29%
EPS (last reported FY) $8.03
EPS (last reported Q) $2.48
EPS, estimated (last reported Q) $2.28
Total revenues $83 B
Net income $15 B